0001104659-23-113580.txt : 20231102 0001104659-23-113580.hdr.sgml : 20231102 20231102071011 ACCESSION NUMBER: 0001104659-23-113580 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231101 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 231370039 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2329618d1_8k.htm FORM 8-K
false 0001346830 0001346830 2023-11-01 2023-11-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 1, 2023

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
(Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which
registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 1, 2023 (the “Closing Date”), Cara Therapeutics, Inc. (the “Company”), through its wholly-owned subsidiary Cara Royalty Sub, LLC, a Delaware limited liability company (“Royalty Sub”), entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) with HCRX Investments Holdco, L.P., a Delaware limited partnership (“HCRx”), and Healthcare Royalty Partners IV, L.P., a Delaware limited partnership (collectively with HCRx, “HCR”). Pursuant to the Purchase and Sale Agreement, Royalty Sub sold, or agreed to sell, as applicable, to HCR certain of its rights to receive royalty payments (the “Royalties”) due and payable to Royalty Sub, on or after October 1, 2023, until such time certain return thresholds are met as described below, under (a) that certain License Agreement, effective as of April 4, 2013, by and between the Company and Maruishi Pharmaceutical Co., Ltd., as amended from time to time and as assigned by the Company to Royalty Sub on the Closing Date (the “Maruishi Agreement”) and (b) that certain License Agreement, dated May 17, 2018, by and between the Company and Vifor Fresenius Medical Care Renal Pharma Ltd., as amended from time to time and as assigned by the Company to Royalty Sub on the Closing Date (the “Vifor Agreement” and, collectively with the Maruishi Agreement, the “Covered License Agreements”) in exchange for up to $40 million in cash. The Vifor Agreement and the Royalties thereunder shall be retained by the Company until the Company has received the First Milestone Payment (as defined below). Further, the Company has retained all of its right, title and interest in, to and under the Covered License Agreements that relate to any non-intravenous formulation of difelikefalin.

 

Under the terms of the Purchase and Sale Agreement, Royalty Sub will receive an upfront payment of $17.5 million, less certain expenses. The terms of the Purchase and Sale Agreement provide for an additional (a) $20 million milestone payment (the “First Milestone Payment”) to Royalty Sub if, prior to December 31, 2023, pricing for Kapruvia® (difelikefalin) in Germany is approved above a certain threshold amount per dose and (b) $2.5 million milestone payment to Royalty Sub upon achievement of a 2024 sales milestone of KORSUVA in Japan.

 

The Purchase and Sale Agreement will automatically expire, and the payment of Royalties to HCR will cease, when HCR has received payments of Royalties equal to two times the aggregate amount of payments made by HCR under the agreement (the “2029 Threshold”), if the 2029 Threshold is achieved on or prior to December 31, 2029, or 2.8 times the aggregate amount of payments made by HCR under the agreement, if the 2029 Threshold is not achieved on or prior to December 31, 2029. After the Purchase and Sale Agreement expires, all rights to receive the Royalties return to Royalty Sub. The Purchase and Sale Agreement grants HCR the right to receive certain reports and other information relating to the Royalties and contains various representations and warranties, covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.

 

On the Closing Date, the Company entered into (i) a Contribution and Servicing Agreement and (ii) a Pledge and Security Agreement. The Contribution and Servicing Agreement contains various representations and warranties, covenants, indemnification obligations and other provisions related to the contribution of the Covered License Agreement to Royalty Sub and the Company’s maintenance and servicing obligations with respect to the Royalties and the Covered License Agreements. The Pledge and Security Agreement contains various representations, warranties and covenants, and includes a limited recourse guaranty of Royalty Sub’s obligations under the Purchase and Sale Agreement which is secured by the pledge in favor of HCR all of the capital stock of Royalty Sub. HCR is entitled to foreclose on the capital stock of Royalty Sub following the occurrence of certain remedies events, including, without limitation, a bankruptcy of the Company or the failure of the Company to perform its obligations under the Contribution and Servicing Agreement.

 

The Company intends to use the proceeds from the Purchase and Sale Agreement to support the ongoing clinical development of its oral difelikefalin pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica.

 

 

 

 

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Purchase and Sale Agreement, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2023.

 

Item 7.01Regulation FD Disclosure.

 

On November 2, 2023, the Company issued a press release announcing the transaction with HCR. A copy of the press release is being furnished to the SEC as Exhibit 99.1 to this Form 8-K and is incorporated by reference to this Item 7.01.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit No. Description
99.1 Press Release, dated November 2, 2023
104 Cover page interactive data file (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.
     
  By: /s/ Christopher Posner
    Christopher Posner
    Chief Executive Officer

 

Date: November 2, 2023

 

 

 

 EX-99.1 2 tm2329618d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

 

Transaction supports progression of late-stage oral difelikefalin clinical programs

 

Non-dilutive capital expected to extend cash runway into 2025

 

STAMFORD, Conn., November 2, 2023 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced it has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty (HCRx).

 

Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral difelikefalin pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica.

 

“This non-dilutive capital strengthens our balance sheet and fuels the continued advancement of our three late-stage oral difelikefalin clinical programs,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “Importantly, this financing is expected to extend our cash runway into 2025.”

 

Under the terms of the agreement, Cara will receive an initial payment of $17.5 million, less certain expenses. Cara will receive an additional payment of $20.0 million upon Kapruvia® (difelikefalin) receiving a certain minimum price in Germany, which is expected to occur this quarter. In addition, if KORSUVA achieves certain specified 2024 performance levels in Japan, Cara will receive a $2.5 million milestone payment. In exchange, HCRx will receive all royalties due to Cara from KORSUVA® (difelikefalin) injection / Kapruvia® ex-U.S. license agreements with CSL Vifor and Maruishi Pharmaceutical Co., Ltd. The arrangement with HCRx specifically excludes KORSUVA injection in the U.S. and all of Cara’s oral difelikefalin internal development programs.

 

The aggregate royalty payments to HCRx are capped at 2.0x the payments to Cara if received before the end of 2029. Otherwise, the payments are capped at 2.8x after which Cara will resume receiving all royalties from both CSL Vifor and Maruishi.

 

Armentum Partners served as financial advisor and Cooley LLP served as legal advisor to Cara. Morgan, Lewis & Bockius LLP acted as legal advisor to HCRx.

 

 

 

 

 

About Cara Therapeutics

 

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with advanced chronic kidney disease and atopic dermatitis. In addition, the Company has an ongoing Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.

 

About HealthCare Royalty

 

HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products and has offices in Stamford (CT), San Francisco, Boston and London. For more information, visit www.hcrx.com. HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the potential for the Company’s product candidates to be alternatives in the therapeutic areas investigated, the potential benefits of the agreement with Healthcare Royalty, the Company’s intended use of proceeds received from the agreement, potential for receipt of milestone payments based off of 2024 performance levels of KORSUVA in Japan, and the pricing for Kapruvia® (difelikefalin) in Germany and the timing thereof. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the launch of new products, including that our commercial partners may not perform as expected, risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

 

 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 

 EX-101.SCH 3 cara-20231101.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20231101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20231101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2329618d1_ex99-1img001.jpg GRAPHIC begin 644 tm2329618d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2023
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2329618d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2023-11-01 2023-11-01 iso4217:USD shares iso4217:USD shares false 0001346830 8-K 2023-11-01 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cara-20231101.xsd cara-20231101_lab.xml cara-20231101_pre.xml tm2329618d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329618d1_8k.htm": { "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20231101", "dts": { "schema": { "local": [ "cara-20231101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cara-20231101_lab.xml" ] }, "presentationLink": { "local": [ "cara-20231101_pre.xml" ] }, "inline": { "local": [ "tm2329618d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://caratherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329618d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329618d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-113580-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-113580-xbrl.zip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end